Generic Name and Formulations:
Sumatriptan (as succinate) 6mg/0.5mL; soln for SC inj.
Indications for ALSUMA:
Acute treatment of migraine or cluster headaches.
Limitations Of use:
Confirm diagnosis; reconsider if no response after treatment. Not for prevention of migraine attacks.
≥18yrs: one (6mg) dose SC to the lateral thigh or upper arm only. Reevaluate if no response. May repeat after 1hr; max two (6mg) doses in 24hrs. Avoid IM or IV administration.
<18yrs: not recommended.
Ischemic coronary artery disease (CAD) (eg, angina, history of MI, silent ischemia). Coronary artery vasospasm (including Prinzmetal's angina). Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders. History of stroke or TIA. History or evidence of hemiplegic or basilar migraine. Peripheral vascular disease. Ischemic bowel disease. Uncontrolled hypertension. Within 24hrs of ergot-type drugs (eg, methysergide, dihydroergotamine) or other 5-HT1 agonists. During or within 2 weeks of an MAO-A inhibitor. Severe hepatic impairment.
Exclude underlying cardiovascular disease, supervise 1st dose, and consider monitoring ECG in patients with multiple cardiovascular risk factors (eg, increased age, diabetes, hypertension, smokers, obesity, strong family history of CAD). Monitor BP, cardiovascular function in long-term intermittent use. Discontinue if serious arrhythmias or cerebrovascular events occur. Peripheral vascular or colonic ischemia following other 5-HT1 agonists. Discontinue if serotonin syndrome is suspected. History, or risk of seizures. Elderly. Pregnancy (Cat.C). Nursing mothers: avoid for 12hrs after dose.
Selective 5-HT1B/1D receptor agonist.
Ergotamines, other 5-HT1 agonists, MAO-A inhibitors: see Contraindications. Increased risk of serotonin syndrome with SSRIs, SNRIs, tricyclics, or MAO inhibitors.
Inj site reactions, tingling, dizziness/vertigo, warm/hot or burning sensation, feeling of heaviness or tightness, pressure sensation, flushing, numbness, tight feeling in head, chest or jaw/nasal cavity/sinuses discomfort, drowsiness/sedation, headache; rare: serious cardiac and cerebrovascular events (including fatalities), hypertension, vision loss, hypersensitivity reactions.
Single-use auto-injector (prefilled)—2/pack
Endocrinology Advisor Articles
- Relationship Between HbA1c and Coronary Artery Disease
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Bone Mineral Density Loss Eventually Stabilizes in Men With Type 1 Diabetes
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- FDA to Review Gimoti for Diabetic Gastroparesis in Adult Women
- FDA Approves First Mobile App for Use in Preventing Pregnancy
- Hypothyroidism Predicts Atrial Tachyarrhythmia After AF Catheter Ablation
- Treating Painful Diabetic Peripheral Neuropathy With Electroacupuncture